[go: up one dir, main page]

ES2166270A1 - Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona. - Google Patents

Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.

Info

Publication number
ES2166270A1
ES2166270A1 ES009901694A ES9901694A ES2166270A1 ES 2166270 A1 ES2166270 A1 ES 2166270A1 ES 009901694 A ES009901694 A ES 009901694A ES 9901694 A ES9901694 A ES 9901694A ES 2166270 A1 ES2166270 A1 ES 2166270A1
Authority
ES
Spain
Prior art keywords
purin
triazolo
dihydro
phenyl
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009901694A
Other languages
English (en)
Other versions
ES2166270B1 (es
Inventor
Ferrer Jordi Gracia
Gras Joan Feixas
Soto Jose Manuel Prieto
Noverola Armando Vega
Juan Bernat Vidal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES009901694A priority Critical patent/ES2166270B1/es
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Priority to CZ2002311A priority patent/CZ2002311A3/cs
Priority to BR0012764-7A priority patent/BR0012764A/pt
Priority to RU2002104935/04A priority patent/RU2258705C2/ru
Priority to EEP200200046A priority patent/EE200200046A/xx
Priority to CNB008130760A priority patent/CN1198825C/zh
Priority to SI200030276T priority patent/SI1198464T1/xx
Priority to SK135-2002A priority patent/SK1352002A3/sk
Priority to EP00949400A priority patent/EP1198464B1/en
Priority to IL14777000A priority patent/IL147770A0/xx
Priority to TR2002/00785T priority patent/TR200200785T2/xx
Priority to HU0202103A priority patent/HUP0202103A3/hu
Priority to JP2001512525A priority patent/JP2003505461A/ja
Priority to ES00949400T priority patent/ES2208378T3/es
Priority to KR1020027001155A priority patent/KR20020022786A/ko
Priority to PL00353827A priority patent/PL353827A1/xx
Priority to HK02103667.4A priority patent/HK1044332B/en
Priority to UA2002010660A priority patent/UA73513C2/uk
Priority to CA002380181A priority patent/CA2380181A1/en
Priority to AT00949400T priority patent/ATE251625T1/de
Priority to AU62772/00A priority patent/AU777571B2/en
Priority to DE60005838T priority patent/DE60005838T2/de
Priority to PCT/EP2000/007062 priority patent/WO2001007441A1/en
Priority to NZ516780A priority patent/NZ516780A/en
Priority to PT00949400T priority patent/PT1198464E/pt
Priority to DK00949400T priority patent/DK1198464T3/da
Priority to PE2000000742A priority patent/PE20010401A1/es
Priority to TW089114927A priority patent/TW568912B/zh
Priority to CO00056184A priority patent/CO5190717A1/es
Priority to MYPI20003424A priority patent/MY129590A/en
Priority to UY26258A priority patent/UY26258A1/es
Priority to ARP000103896A priority patent/AR024969A1/es
Priority to ZA200200561A priority patent/ZA200200561B/en
Priority to BG06346A priority patent/BG106346A/xx
Priority to NO20020391A priority patent/NO20020391L/no
Priority to US10/057,847 priority patent/US7034016B2/en
Publication of ES2166270A1 publication Critical patent/ES2166270A1/es
Application granted granted Critical
Publication of ES2166270B1 publication Critical patent/ES2166270B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Derivados de 8-fenil-6,9-dihidro[1,2,4]triazolo[3,4-i]purin-5-ona de fórmula (I): **FIGURA** en donde: R{sup,1}, R{sup,2} y R{sup,3} cada uno independientemente representan: hidrógeno; un grupo orgánico lineal ramificado o cíclico sustituido o no sustituido, cicloalifático o aromático, homocíclico o heterocíclico, R{sup,4} y R{sup,5} juntos con el átomo de nitrógeno al cual están unidos forman un anillo de 3 a 7 miembros que comprende un total de 1 a 4 heteroátomos seleccionados entre nitrógeno, oxígeno y azufre, cuyo anillo puede estar no sustituido o sustituido; o R{sup,4} y R{sup,5} representan independientemente un átomo de hidrógeno o un grupo alquilo el cual puede estar no sustituido o sustituido, o R{sup,4} representa hidrógeno o un grupo alquilo y R{sup,5} representa un grupo de fórmula -(CH{sub,2}){sub,n}-R{sup,7} en donde n es un número del 0 al 4 y R{sup,7} representa: un grupo orgánico; o R{sup,4} y R{sup,5} representan grupos hidroxilo, alcoxilo, hidroxialcoxilo, fenilo, alcoxicarbonilo, amino, mono- o di- alquilamino o hidroxi carbonilo; o una sal farmacéuticamente aceptable de los mismos; procedimientos para su preparación, composiciones farmacéuticas que los contengan y su uso como inhibidores de la PDE 5.
ES009901694A 1999-07-27 1999-07-27 Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona. Expired - Fee Related ES2166270B1 (es)

Priority Applications (36)

Application Number Priority Date Filing Date Title
ES009901694A ES2166270B1 (es) 1999-07-27 1999-07-27 Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
AT00949400T ATE251625T1 (de) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-(1,2,4)triazolo(3,4-i)puri - 5-on derivate
RU2002104935/04A RU2258705C2 (ru) 1999-07-27 2000-07-24 ПРОИЗВОДНЫЕ 8-ФЕНИЛ-6,9-ДИГИДРО[1,2,4]-ТРИАЗОЛО[3,4-i]ПУРИН-5-ОНА, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ
EEP200200046A EE200200046A (et) 1999-07-27 2000-07-24 8-fenüül-6,9-dihüdro-[1,2,4]triasolo[3,4-i]puriin-5-ooni derivaat, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
CNB008130760A CN1198825C (zh) 1999-07-27 2000-07-24 8－苯基－6,9－二氢－[1,2,4]三唑并[3,4－i]嘌呤－5－酮衍生物
SI200030276T SI1198464T1 (en) 1999-07-27 2000-07-24 8-PHENYL-6,9-DIHYDRO-(1,2,4)TRIAZOLO(3,4-i)PURIN-5-ONE DERIVATIVES
SK135-2002A SK1352002A3 (en) 1999-07-27 2000-07-24 8-Phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives
EP00949400A EP1198464B1 (en) 1999-07-27 2000-07-24 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES
IL14777000A IL147770A0 (en) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-[1,2,4] triazolo[3,4-i] purin-5-one derivatives
TR2002/00785T TR200200785T2 (tr) 1999-07-27 2000-07-24 8-Fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-on türevleri
HU0202103A HUP0202103A3 (en) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives, their use, pharmaceutical compositions containing them, process for the preparation of the compounds and intermediates
JP2001512525A JP2003505461A (ja) 1999-07-27 2000-07-24 ８−フェニル−６，９−ジヒドロ−［１，２，４］トリアゾロ［３，４−ｉ］プリン−５−オン誘導体
ES00949400T ES2208378T3 (es) 1999-07-27 2000-07-24 Derivados de 8-fenil-6,9-dihidro-1,2,4)triazolo(3,4-i)purin-5-onas.
KR1020027001155A KR20020022786A (ko) 1999-07-27 2000-07-24 8-페닐-6,9-디히드로-[1,2,4]트리아졸로[3,4-ｉ]푸린-5-온유도체
BR0012764-7A BR0012764A (pt) 1999-07-27 2000-07-24 Composto, processo para preparar um composto, composição farmacêutica, uso de um composto e método de tratar um paciente humano ou animal
HK02103667.4A HK1044332B (en) 1999-07-27 2000-07-24 8-Phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-I]purin-5-one derivative
UA2002010660A UA73513C2 (en) 1999-07-27 2000-07-24 8-PHENYL-6,9 ûDIHYDRO- [1,2,4] TRIAZOLO [3,4-I] PURIN û5-ON DERIVATIVES, A METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON
CA002380181A CA2380181A1 (en) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-¬1,2,4|triazolo¬3,4-i|purin-5-one derivatives
CZ2002311A CZ2002311A3 (cs) 1999-07-27 2000-07-24 8-Fenyl-6,9-dihydro/1,2.4/triazolo/3,4-i/purin-5-onové deriváty
PL00353827A PL353827A1 (en) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i
PE2000000742A PE20010401A1 (es) 1999-07-27 2000-07-24 DERIVADOS DE 8-FENIL-6,9-DIHIDRO-[1,2,4] TRIAZOL [3,4-i] PURIN-5-ONA COMO INHIBIDORES DE FOSFODIESTERASA ESPECIFICA DE GMP CICLICO
PCT/EP2000/007062 WO2001007441A1 (en) 1999-07-27 2000-07-24 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES
NZ516780A NZ516780A (en) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives
PT00949400T PT1198464E (pt) 1999-07-27 2000-07-24 Derivados 8-fenil-6,9-di-hidro-¬1,2,4|triazolo¬3,4-i|puri-5-ona
DK00949400T DK1198464T3 (da) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro[1,2,4]triazolo[3,4-i]purin-5-onderivater
DE60005838T DE60005838T2 (de) 1999-07-27 2000-07-24 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ON DERIVATE
AU62772/00A AU777571B2 (en) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-(1,2,4)triazolo(3,4-i)purin-5-one derivatives
TW089114927A TW568912B (en) 1999-07-27 2000-07-26 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives
CO00056184A CO5190717A1 (es) 1999-07-27 2000-07-26 Derivados de 8-fenil-6,9 dihidro-[1,2,4]triazol[3,4,i] purin-5-ona
MYPI20003424A MY129590A (en) 1999-07-27 2000-07-26 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES
ARP000103896A AR024969A1 (es) 1999-07-27 2000-07-27 Derivados de 8-fenil-6,9-dihidro-[1,2,4]triazol[3,4-i]purin-5-ona
UY26258A UY26258A1 (es) 1999-07-27 2000-07-27 Derivados de 8-fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-ona.
ZA200200561A ZA200200561B (en) 1999-07-27 2002-01-22 8-phenyl-6,9-dihydro[1,2,4]triazolo[3,4-i]purin-5-one derivatives.
BG06346A BG106346A (en) 1999-07-27 2002-01-24 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO-[3,4-i]PURIN-5-ONE DERIVATIVES
US10/057,847 US7034016B2 (en) 1999-07-27 2002-01-25 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives
NO20020391A NO20020391L (no) 1999-07-27 2002-01-25 8-Fenyl-6,9-dihydro-[1,2,4]-triazolo [3,4-i]-purin-5-on- derivater

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009901694A ES2166270B1 (es) 1999-07-27 1999-07-27 Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.

Publications (2)

Publication Number Publication Date
ES2166270A1 true ES2166270A1 (es) 2002-04-01
ES2166270B1 ES2166270B1 (es) 2003-04-01

Family

ID=8309393

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009901694A Expired - Fee Related ES2166270B1 (es) 1999-07-27 1999-07-27 Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
ES00949400T Expired - Lifetime ES2208378T3 (es) 1999-07-27 2000-07-24 Derivados de 8-fenil-6,9-dihidro-1,2,4)triazolo(3,4-i)purin-5-onas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00949400T Expired - Lifetime ES2208378T3 (es) 1999-07-27 2000-07-24 Derivados de 8-fenil-6,9-dihidro-1,2,4)triazolo(3,4-i)purin-5-onas.

Country Status (34)

Country Link
US (1) US7034016B2 (es)
EP (1) EP1198464B1 (es)
JP (1) JP2003505461A (es)
KR (1) KR20020022786A (es)
CN (1) CN1198825C (es)
AR (1) AR024969A1 (es)
AT (1) ATE251625T1 (es)
AU (1) AU777571B2 (es)
BG (1) BG106346A (es)
BR (1) BR0012764A (es)
CA (1) CA2380181A1 (es)
CO (1) CO5190717A1 (es)
CZ (1) CZ2002311A3 (es)
DE (1) DE60005838T2 (es)
DK (1) DK1198464T3 (es)
EE (1) EE200200046A (es)
ES (2) ES2166270B1 (es)
HK (1) HK1044332B (es)
HU (1) HUP0202103A3 (es)
IL (1) IL147770A0 (es)
MY (1) MY129590A (es)
NO (1) NO20020391L (es)
NZ (1) NZ516780A (es)
PE (1) PE20010401A1 (es)
PL (1) PL353827A1 (es)
PT (1) PT1198464E (es)
RU (1) RU2258705C2 (es)
SK (1) SK1352002A3 (es)
TR (1) TR200200785T2 (es)
TW (1) TW568912B (es)
UA (1) UA73513C2 (es)
UY (1) UY26258A1 (es)
WO (1) WO2001007441A1 (es)
ZA (1) ZA200200561B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SE0300917D0 (sv) 2003-03-31 2003-03-31 St Jude Medical Multi-chamber pacing system
PT1644021E (pt) * 2003-06-13 2013-01-30 Ironwood Pharmaceuticals Inc Métodos e composições para o tratamento de distúrbios gastrointestinais
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
AU2005243192A1 (en) * 2004-04-29 2005-11-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AU2005307861B2 (en) * 2004-11-18 2009-11-12 Schering Corporation Methods of using PDE V inhibitors for the treatment of congestive heart failure
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
KR101541791B1 (ko) 2006-05-04 2015-08-04 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20110103968A (ko) 2008-12-23 2011-09-21 베링거 인겔하임 인터내셔날 게엠베하 유기 화합물의 염 형태
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
ES2934843T3 (es) 2011-07-15 2023-02-27 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
IN2015DN00334A (es) 2012-06-18 2015-06-12 Dart Neuroscience Cayman Ltd
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CA3087655A1 (en) * 2018-01-04 2019-07-11 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof
TWI837171B (zh) * 2018-08-30 2024-04-01 日商鐵勒史東股份有限公司 用於抑制黃嘌呤氧化酶之肼基嘌呤化合物及三唑嘌呤化合物
CN112225761B (zh) * 2020-12-16 2021-03-12 南京颐媛生物医学研究院有限公司 一种嘧啶并三氮唑及其合成方法
EP4305033B1 (en) * 2021-03-09 2025-05-07 Basf Se Tricyclic pesticidal compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0149200A1 (de) * 1983-12-28 1985-07-24 Dr. Karl Thomae GmbH Neue 2-Phenyl-imidazole, ihre Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0417790A2 (en) * 1989-09-14 1991-03-20 Kyowa Hakko Kogyo Co., Ltd. S-triazolo[3,4-i]purine derivatives
EP0463756A1 (en) * 1990-06-20 1992-01-02 Pfizer Limited Pyrazolopyrimidinone antianginal agents
WO1998049166A1 (en) * 1997-04-25 1998-11-05 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
IL98559A0 (en) * 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
US5990118A (en) * 1995-02-21 1999-11-23 Yamasa Corporation Purine compounds and xanthine oxidase inhibitors
WO1999062905A1 (en) * 1998-06-03 1999-12-09 Almirall Prodesfarma, S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
AU2001289782A1 (en) * 2000-08-09 2002-02-18 Almirall Prodesfarma, S.A. Pyrrolotriazolopyrimidinone derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0149200A1 (de) * 1983-12-28 1985-07-24 Dr. Karl Thomae GmbH Neue 2-Phenyl-imidazole, ihre Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0417790A2 (en) * 1989-09-14 1991-03-20 Kyowa Hakko Kogyo Co., Ltd. S-triazolo[3,4-i]purine derivatives
EP0463756A1 (en) * 1990-06-20 1992-01-02 Pfizer Limited Pyrazolopyrimidinone antianginal agents
WO1998049166A1 (en) * 1997-04-25 1998-11-05 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION

Also Published As

Publication number Publication date
CO5190717A1 (es) 2002-08-29
HUP0202103A2 (en) 2002-10-28
AU6277200A (en) 2001-02-13
DE60005838T2 (de) 2004-08-19
TR200200785T2 (tr) 2002-09-23
AU777571B2 (en) 2004-10-21
PT1198464E (pt) 2004-02-27
US7034016B2 (en) 2006-04-25
HUP0202103A3 (en) 2004-12-28
MY129590A (en) 2007-04-30
SK1352002A3 (en) 2003-04-01
ATE251625T1 (de) 2003-10-15
AR024969A1 (es) 2002-10-30
CN1198825C (zh) 2005-04-27
CZ2002311A3 (cs) 2003-01-15
HK1044332A1 (en) 2002-10-18
PL353827A1 (en) 2003-12-01
HK1044332B (en) 2004-10-15
EP1198464A1 (en) 2002-04-24
JP2003505461A (ja) 2003-02-12
ES2166270B1 (es) 2003-04-01
PE20010401A1 (es) 2001-04-16
EE200200046A (et) 2003-04-15
UA73513C2 (en) 2005-08-15
KR20020022786A (ko) 2002-03-27
RU2258705C2 (ru) 2005-08-20
NZ516780A (en) 2004-01-30
CN1374962A (zh) 2002-10-16
IL147770A0 (en) 2002-08-14
BR0012764A (pt) 2002-07-02
TW568912B (en) 2004-01-01
NO20020391L (no) 2002-03-25
US20030060627A1 (en) 2003-03-27
WO2001007441A1 (en) 2001-02-01
BG106346A (en) 2002-09-30
NO20020391D0 (no) 2002-01-25
ES2208378T3 (es) 2004-06-16
CA2380181A1 (en) 2001-02-01
EP1198464B1 (en) 2003-10-08
ZA200200561B (en) 2003-06-25
DK1198464T3 (da) 2004-02-16
DE60005838D1 (de) 2003-11-13
UY26258A1 (es) 2000-12-29

Similar Documents

Publication Publication Date Title
ES2166270A1 (es) Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
HUP0300565A3 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
MY132642A (en) Naphthyridine derivatives
HK1046527A1 (zh) 金剛烷衍生物
HUP0200804A3 (en) The use of pharmaceutical compositions containing 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
IE900161L (en) Pyrazolopyridines
CA2400268A1 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
HUP0200572A2 (en) Amine derivatives as protease inhibitors process for their preparation, pharmaceutical compositions containing them and their use
AU5895496A (en) Phenyldihydrobenzofurans
HUP0204143A3 (en) Tricyclic 1-benzylpyrazole-3-carboxylic acid derivatives, preparation of the compounds, their use and pharmaceutical compositions containing them
WO2002048148A3 (en) Pyrazolopyridine derivatives
HUP0200881A2 (en) Renin inhibitors, process for preparation of the compounds, pharmaceutical compositions containing them and their use
CA2307101A1 (en) Pharmaceutical articles of manufacture comprising selective phosphodiesterase inhibitors for the treatment of sexual dysfunction
HUP0202233A3 (en) Derivatives and analogues of galanthamin, their use, pharmaceutical compositions containing them and process for the preparation of them
HUP9801993A3 (en) Ascomycin derivatives and their use for preparation of pharmaceutical compositions, process for their preparation and pharmaceutical compositions containing them
IL125628A0 (en) Benzo[c] quinolizine derivatives their preparation and use as 5alpha-reductase inhibitors
AU7270798A (en) Antithrombotic agents
IL108085A0 (en) Serotoninergic ergoline derivatives their preparation and pharmacutical compositions containing them
HUP0202988A3 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one derivatives and their use as lipase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO1999005103A3 (en) 2o(s)-7-ethyl-9-(n-methyl-n-phenyl)amidino-camptothecin, its preparation and its use as antitumor agent
HUP0400773A3 (en) 7-(4-tert-butylyclohexyl)-5-ethyl-3h-imidazo[5,1-f][1,2,4]triazin-4-on derivatives, their use pharmaceutical compositions containing them and process for the preparation of the compounds
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
ZA986730B (en) Streptogramin derivatives their preparation and compositions containing them
HUP0401912A3 (en) Pharmaceutically acceptable salts of 20(s)-camptothecins, process for their preparation and pharmaceutical compositions containing them
CA2245758A1 (en) Benzo[c]quinolizine derivatives, their preparation and use as 5.alpha.-reductases inhibitors

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020401

Kind code of ref document: A1

Effective date: 20020401

FG2A Definitive protection

Ref document number: 2166270B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20100528